BCLI · Brainstorm Cell Therapeutics Inc.
$0.90
-0.03 (-3.23%)
At close · Jul 28
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan includes raising funds from outside potential investors, however, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives.”View the 10-Q filed May 15, 2026
Market Cap
$9.93M
Shares
11.03M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$10.31M
+11.3%
FY2025
Diluted EPS
-$1.11
+51.9%
FY2025
Operating Cash Flow
-$6.98M
+23.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.63M | $4.18M | $4.65M | $10.75M | $13.96M | $15.24M | $22.33M | $17.2M | $8.29M | $977K | $2.25M | $4.95M | $4.77M | $2.92M | $1.77M | $1.69M | $1.05M | — | — | — | |
| $5.28M | $5.78M | $7.04M | $10.69M | $10.87M | $9.3M | $9.36M | $5.8M | $5.77M | $4.02M | $2.83M | $3.59M | $2.65M | $2.13M | $1.75M | $2.21M | $1.54M | — | — | — | |
| $8.6M | — | — | — | — | — | — | — | — | — | — | — | $7.42M | $5.04M | $3.52M | $3.89M | $2.59M | — | — | — | |
| -$8.91M | -$9.95M | -$11.69M | -$21.44M | -$24.82M | -$24.54M | -$31.68M | -$23M | -$14.06M | -$5M | -$5.08M | -$8.54M | -$7.42M | -$4.9M | -$3.43M | -$3.91M | $2.4M | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $2.45M | $151K | $189K | — | — | — | |
| — | -$10.31M | -$11.62M | -$17.19M | -$24.28M | -$24.46M | -$31.81M | -$23.25M | -$13.95M | -$4.95M | -$4.98M | -$8.49M | -$9.25M | -$4.9M | -$3.43M | -$3.92M | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $5000 | $5000 | -$19K | — | — | — | |
| -$9.57M | -$10.31M | -$11.62M | -$17.19M | -$24.28M | -$24.46M | -$31.81M | -$23.25M | -$13.95M | -$4.95M | -$4.98M | -$8.49M | -$9.25M | -$4.9M | -$3.43M | -$3.92M | -$2.42M | -$1.78M | -$3.47M | -$6.24M | |
| USD/shares | — | -$1.11 | -$2.31 | -$6.00 | -$9.90 | -$10.20 | -$16.05 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$1.11 | -$2.31 | -$6.00 | -$9.90 | -$10.20 | -$16.05 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 9.27M | 5.02M | 2.87M | 2.43M | 2.41M | 1.99M | 1.46M | 1.33M | 1.25M | 1.24M | 1.23M | 910.85K | 715.88K | 9.17M | 8.01M | — | — | — | — |
| shares | — | 9.27M | 5.02M | 2.87M | 2.43M | 2.41M | 1.99M | 1.46M | 1.33M | 1.25M | 1.24M | 1.23M | 910.85K | 715.88K | 9.17M | 8.01M | — | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Peer median 0.04×
Peer medians compare against the 191 similar-size Biotechnology companies (of 522 listed).